Health
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net
Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences,…
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…
Continue Reading
-
General11 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General14 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News13 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business11 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher